Reprogramming the Future of Cancer Treatment.
The first biotechnology company in the Kashmir Valley pioneering next-generation cancer therapies. Our CAR-T cell and oncolytic virus platforms are designed to target and eliminate cancer with precision.
Advanced Cancer Medicine
Worem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum
Global
New Cancer Cases in 2022
Source: IARC/GLOBOCAN 2022
Global Burden
Add your extra details here, such as trends, mortality figures or a short note about the global picture.
India
New Cancer Cases in 2022
98.5 per 100,000
Source: IARC/GLOBOCAN 2022
Cancer in India
Add your extra details here, such as common cancer types, mortality or screening information.
Jammu & Kashmir
New Cancer Cases in 2022
7,396 Deaths in 2022
Source: IARC/GLOBOCAN 2022
Cancer in J&K
Add your extra details here, such as regional trends, awareness or screening information.
Redefining Cancer Care Through
Breakthrough Science
targeted small molecules united by a single goal: precisely destroying cancer cells while triggering durable,
systemic immune responses.
OUR PIPELINE
Targeting cancer at its
molecular root.
Our pipeline bridges translational research and clinical application, integrating deep scientific expertise with state-of-the-art technologies to deliver safe, effective, and accessible therapeutic solutions.
HT-09 is a proprietary peptide developed to address one of the most critical unmet needs in modern cancer immunotherapy: the generation and maintenance of durable, long-lived immune responses.
A novel immune-therapeutic technology.
Our Approach
-
Biology-Driven Discovery - We begin with a deep understanding of cancer biology to identify actionable vulnerabilities and develop differentiated therapeutic opportunities where existing treatments fall short.
-
Multi-Modality Precision - We integrate precision small molecules, engineered cell therapies, and oncolytic virus platforms to attack tumors through complementary mechanisms. Each program is designed to maximize anti-tumor activity, limit effects on healthy tissue, and support durable responses
-
Translation With Purpose - We advance high-potential discoveries through disciplined preclinical development and strategic scientific and clinical collaboration, building toward therapies that can deliver meaningful benefit for patients with hard-to-treat cancers.
Our Team
Decades of experience, one bold mission
Augustus Therapeutics brings together scientific and drug-development expertise to build a new generation of cancer medicines. Our team integrates tumor biology, immune engineering, medicinal chemistry, and translational research to advance a differentiated pipeline of precision small molecules, engineered cell therapies, and oncolytic virus platforms.
Prof. Jacob Gopas
Scientific Advisor
Focus
Prof. Jacob Gopas is the Scientific Advisor to Augustus Therapeutics, guiding the scientific direction of the company's research programs.
1/2
Latest News
Harnessing Immunotherapy to Transform the Future of Healthcare
Immunotherapy continues to redefine how researchers approach complex diseases by leveraging the body’s own immune system to fight illness.
From Discovery to Clinical Development: The Journey of a Therapeutic Candidate
Bringing a new therapy from the laboratory to patients requires years of rigorous research, testing, and collaboration. Here’s an overview of the development process.
The Future of Precision Medicine: Why Personalized Therapies Matter
Modern medicine is moving beyond one-size-fits-all treatments. Discover how precision medicine is reshaping healthcare by developing therapies tailored to individual patients and specific disease mechanisms.